Table 1:
Baseline characteristics of the study population. Results are shown as mean ± standard deviation, n (%) or median (interquartile range).
| Total Subjects N=2068 | MACE + N=223 | MACE – N=1845 | P-value | |
|---|---|---|---|---|
| Demographics | ||||
| Age (years) | 56.1 ± 9.1 | 60.0 ± 9.9 | 55.6 ± 8.8 | <0.001* |
| Male | 1226 (59%) | 155 (70%) | 1071 (58%) | 0.001* |
| BMI (kg/m2) | 26.6 ± 4.9 | 27.7 ± 5.2 | 26.5 ± 4.8 | <0.001* |
| Waist circumference (cm) | 36.1 ± 5.4 | 37.2 ± 5.7 | 35.9 ± 5.3 | 0.03* |
| Cardiovascular risk factors | ||||
| ASCVD risk score (%) | 7.5 ± 7.6 | 12.8 ± 11.2 | 6.8 ± 6.8 | <0.001* |
| Diabetes mellitus | 119 (6%) | 20 (9%) | 99 (5%) | 0.03* |
| Hypertension | 834 (40%) | 133 (60%) | 701 (38%) | <0.001* |
| Hyperlipidemia | 1439 (70%) | 168 (75%) | 1271 (69%) | 0.05 |
| Smoking | 91 (4%) | 10 (4%) | 81 (4%) | 0.55 |
| Family history of CAD | 623 (30%) | 77 (35%) | 546 (30%) | 0.13 |
| Medications | ||||
| Statin | 447 (22%) | 58 (26%) | 389 (21%) | 0.10 |
| Aspirin | 127 (6%) | 26 (12%) | 101 (5%) | 0.01* |
| ACE/ARB | 163 (8%) | 32 (14%) | 131 (7%) | <0.001* |
| HTN medication | 345 (17%) | 64 (29%) | 281 (15%) | <0.001†=* |
| Baseline measurements | ||||
| Total cholesterol (mg/dL) | 210.9 ± 40.1 | 212.7 ± 43.6 | 210.7 ± 39.7 | 0.71 |
| LDL-cholesterol (mg/dL) | 131.3 ± 37.2 | 135.5 ± 45.8 | 130.7 ± 36.0 | 0.32 |
| CAC score (AU) * | 0 (0.0–56.4) | 116.3 (6.3–527.0) | 0 (0–35.5) | <0.001* |
| EAT volume (cm3) | 78.5 (55.9–106.0) | 90.6 (67.4–128.7) | 77.0 (54.7–103.3) | <0.001* |
| EAT attenuation (HU) | −73.8 ± 4.8 | −75.4 ± 5.13 | −73.6 ± 4.7 | <0.001* |
Abbreviations: ACE: angiotensin-converting enzyme, ARB: angiotensin II receptor blocker, ASCVD: atherosclerotic cardiovascular disease, BMI: body mass index, CAC: coronary artery calcium, CAD: coronary artery diseaseEAT: epicardial adipose tissue, HTN: hypertension, LDL: low-density lipoprotein, MACE: major adverse cardiovascular events
*
P-values <0.05 are statistically significant.